東瑞製藥(02348.HK)2019年淨利降15.97%至2.55億元
格隆匯3月28日丨東瑞製藥(02348.HK)發佈公告,截至2019年12月31日止年度,實現收入9.5億元人民幣(單位下同),同比增長0.1%;母公司擁有人應占年度溢利2.55億元,同比減15.97%;基本每股盈利0.1621元;擬派末期股息:每普通股港幣0.043元。
於回顧期內,在競爭激烈的市場環境下,集團治療高血壓的安系列產品的銷售量,比2018年度增長18.2%。恩替卡韋分散片銷售量增長32.5%,抗過敏藥物西可韋(鹽酸西替利嗪片)與上年持平。頭孢菌素類成品藥銷售相對穩定。頭孢菌素中間體及原料藥由於集團不斷提高產品質量,降低生產成,中間體及原料藥產品競爭能力較大提高,銷售量增長7.5%。
期內,集團營銷管理人員因應市場急促變化,適當調整集團產品營銷思路和銷售策略並加強配置資源,優化供銷體系,拓展新的市場。集團積極抓住國家聯盟地區集採的機遇,在聯盟地區藥品集中採購中,集團三個主要產品“安內真”(苯磺酸氨氯地平片5mg)、“瑞夫恩”(恩替卡韋分散片0.5mg)、“舒邁通”(阿託伐他汀鈣片10mg)中標,為集團產品佔領市場,樹立品牌將發生積極作用。集團營銷管理人員將利用這一契機持續深化市場工作,以促使各層級市場的組織管控更趨完善,盡力確保該以上產品銷售在2020年取得合理增長,於集團的盈利作出貢獻。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.